State of the Science: Screening, Surveillance, and Epidemiology of HPV-Related Malignancies

Oropharyngeal, cervical, vulvar, and anal cancers share a common risk factor of HPV infection. vaccination is currently recommended at age 11 or 12 to prevent new infections for all genders with catch-up recommened up 26. Despite the known effectiveness HPV-related cancer, there continued low uptake in United States; only 40% eligible persons were vaccinated 2018, though rates are 70% among teenagers. Current American Cancer Society cancer screening guidelines recommend cervical screening, but do not have specific recommendations other cancers. Oropharyngeal precursors yet be identified, no routine tests oropharyngeal by U.S. Preventive Services Task Force. The Force women average 65, differ status. Primary DNA testing was first approved 2016 shown superior prevention. Vulvar been optimal remains unclear. Examination canal perianus best performed trained clinicians using high-resolution anoscopy, anoscopy detect treat high-grade squamous intraepithelial lesions actively being researched. multistep approaches control malignancies include coupled surveillance oropharyngeal,